Pediatric Brain Tumor Populations Too Small For Non-Inferiority Trials – Cmte
Executive Summary
The heterogeneity of pediatric brain tumors generally precludes the use of non-inferiority trials to support approval, FDA's Pediatric Oncology Subcommittee determined
You may also be interested in...
Progression-Free Survival Is Meaningful Endpoint For Glioma Trials
Progression free survival assessed at six months should be considered as a meaningful surrogate endpoint in evaluating primary brain tumor clinical trials for accelerated approval, a panel assembled by FDA agreed
NDAs Should Include More Cross-Study Analysis, FDA Says In Draft Guidance
FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications
New Look At Ezetimibe Fails To Confirm Vytorin Cancer Signal
Interim data from SHARP and IMPROVE-IT trials fail to show evidence of impact on cancer rates.